Two inhalants were approved on the same day, and Chia Tai Tianqing won the first domestic company

Recently, the official website of the State Food and Drug Administration showed that the methacholine for inhalation of Chia Tai Tianqing Pharmaceutical Group and the levosalbutamol hydrochloride atomized inhalation solution of Jiangsu Changtai Pharmaceutical Co.
, Ltd.
were approved for production on the same day as the imitation category 3.
Among them, Chia Tai Tianqing Pharmaceutical Group's methacholine for inhalation is the first domestic company
.
According to the latest data from Minet.
com, in 2021, the sales of terminal inhalants in public hospitals in key cities will exceed 3.
5 billion yuan
.
The TOP10 varieties have made a big counterattack, 7 products have double-digit growth, and 3 major domestic brands have performed well
.
Since the beginning of this year, five inhalant varieties have been approved for marketing
.
Up to now, there are more than 100 products of inhalants (calculated by the name of the drug + the name of the declared enterprise) under the new registration classification, and more than 40 varieties (calculated by the name of the drug) are involved.
Special, Chia Tai Tianqing and many other companies sprint for the first imitation
.
Two inhalers were approved on the same day! Chia Tai Tianqing won the first domestically produced drug approval certificate on March 24, 2022 to receive information.
Recently, the official website of the State Food and Drug Administration showed that Chia Tai Tianqing's inhalation methacholine and Jiangsu Changtai Pharmaceutical's hydrochloric acid Levosalbutamol aerosol inhalation solution was approved on the same day as the imitation Category 3, which is regarded as over-evaluation
.
Among them, Chia Tai Tianqing's methacholine for inhalation is the first domestic company
.
Source of approval of methacholine for inhalation: Minenet new version database Methacholine for inhalation is suitable for the diagnosis of bronchial airway hyperresponsiveness in adults without clinically significant asthma and in children aged 5 years and over.
Aerosol inhalation administration
.
The original research product has not yet been listed in China.
The methacholine for inhalation developed by Chia Tai Tianqing is the only provocative agent approved for bronchial provocation test in China
.
Sales of levalbuterol hydrochloride atomized inhalation solution in public hospitals in key cities in recent years (unit: RMB 10,000) Source: MINET.
com Competitive landscape of public hospitals in key cities The growth rate of solution sales is astonishing, with a year-on-year increase of more than 2000%
.
This time, Jiangsu Changtai Pharmaceutical Co.
, Ltd.
was approved for the levosalbutamol hydrochloride atomized inhalation solution, which was reported to be a generic type 3 product, becoming the fifth domestic enterprise of this product
.
At present, levosalbutamol hydrochloride atomized inhalation solution has production approvals from 6 companies including Jiankangyuan, Jiangsu Dahongying Hengshun Pharmaceutical, Jiangxi Esther Pharmaceutical, Yangzijiang Pharmaceutical Group Jiangsu Zilong Pharmaceutical | Yangzijiang Pharmaceutical Group, etc.
4 The company's report is under review and approval
.
Inhalant counterattack! 7 double-digit growth of TOP10 products Quarterly sales of terminal inhalants in public hospitals in key cities in recent years (unit: 100 million yuan) Source: MINET.
com Competitive landscape of public hospitals in key cities The market is growing steadily, with a growth rate of more than 10% in 2019.
Affected by the epidemic in 2020, sales will decline.
In 2021, it will return to double-digit growth, with sales exceeding 3.
5 billion yuan
.
Judging from the quarterly sales situation, after experiencing the low ebb in Q1 and Q2 in 2020, the market has gradually recovered
.
2021 TOP10 terminal inhalants in public hospitals in key cities Source: Minet.
com Key city public hospitals terminal competition pattern The market concentration of inhalants is relatively high, with the top 10 products accounting for more than 70% of the total market share, and the top 3 products being budesonide suspension for inhalation The total market share of sevoflurane for inhalation and acetylcysteine ​​solution for inhalation accounts for "half of the country"
.
7 products have double-digit growth, among which, terbutaline sulfate aerosol inhalation solution and mometasone furoate nasal spray have increased by more than 50%
.
In 2020, only 2 of the top 10 inhalation products have positive growth
.
Among the top 10 brands, there are 3 domestic brands on the list, namely sevoflurane for inhalation from Shanghai Hengrui Pharmaceutical, acetylcysteine ​​solution for inhalation from Hainan Star Pharmaceutical, and budesonide for inhalation from Chia Tai Tianqing Pharmaceutical Group.
German suspension
.
Among them, Chia Tai Tianqing Pharmaceutical Group's budesonide suspension for inhalation jumped to seventh place by virtue of centralized procurement, with sales increasing by more than 300% year-on-year, while AstraZeneca declined slightly
.
It is worth mentioning that inhalants have appeared since the fourth batch of national procurement.
At present, a total of 4 varieties have been included in the national procurement, salbutamol sulfate solution for inhalation (the fourth batch), and compound ipratropium bromide solution for inhalation.
(The fifth batch), budesonide suspension for inhalation (the fifth batch), and ipratropium bromide solution for inhalation (the fifth batch), the market share of the winning bidders has increased
.
And terbutaline inhalation entered the seventh batch of the proposed centralized procurement list, involving AstraZeneca, Siqipu Ruite Pharmaceutical, Hebei Renhe Yikang Pharmaceutical, Shijiazhuang No.
4 Medicine, Suzhou Hongsen Pharmaceutical and other enterprises.
Minet will continue to pay attention to how the market pattern of varieties will change
.
20 inhalants are dazzling, health yuan, Hengrui, four Trump Ruite.
.
.
sprint the first imitation new classification (imitation category 3, 4), the inhalation is under review and there is no first imitation source: Minet MED2.
0 China Drug Evaluation Database Since the beginning of this year, 5 inhalant varieties have been approved for marketing.
Among them, levosalbutamol hydrochloride atomized inhalation solution has the most approved companies.
There are 4 Thai Pharmaceuticals and Jiangsu Dahongying Hengshun Pharmaceuticals
.
Up to now, there are more than 100 products of inhalants (calculated by the name of the drug + the name of the declared enterprise) under the new registration classification, and more than 40 varieties (calculated by the name of the drug) are involved.
Special, Chia Tai Tianqing and many other companies sprint for the first imitation
.
According to the data of Minet.
com, the global sales of salmeterol, ticasone, fluticasone and lanvitrol in 2021 are all blockbuster varieties of over US$1 billion.
We will wait and see who will successfully win the first imitation
.
Source: State Food and Drug Administration official website, company announcements, Minet database Note: The competition pattern of chemical drug terminals in public hospitals in key cities of Minet A sample city sample hospital database for continuous monitoring of all categories of chemical drugs
.
The statistics are as of March 29.
If there are any omissions, please correct me!